# Ensuring Access to Optimal Therapy in CF: The ENACT Study

> **NCT07148739** · PHASE4 · RECRUITING · sponsor: **Arkansas Children's Hospital Research Institute** · enrollment: 95 (estimated)

## Conditions studied

- Cystic Fibrosis (CF)

## Interventions

- **DRUG:** Elexacaftor / Ivacaftor / Tezacaftor
- **OTHER:** therapeutic drug monitoring

## Key facts

- **NCT ID:** NCT07148739
- **Lead sponsor:** Arkansas Children's Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-10
- **Primary completion:** 2030-12
- **Final completion:** 2030-12
- **Target enrollment:** 95 (ESTIMATED)
- **Last updated:** 2025-08-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07148739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07148739, "Ensuring Access to Optimal Therapy in CF: The ENACT Study". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT07148739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*